[go: up one dir, main page]

WO2009053549A8 - Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant - Google Patents

Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant Download PDF

Info

Publication number
WO2009053549A8
WO2009053549A8 PCT/FR2008/001158 FR2008001158W WO2009053549A8 WO 2009053549 A8 WO2009053549 A8 WO 2009053549A8 FR 2008001158 W FR2008001158 W FR 2008001158W WO 2009053549 A8 WO2009053549 A8 WO 2009053549A8
Authority
WO
WIPO (PCT)
Prior art keywords
same
rimonabant
pharmaceutical compositions
compositions containing
dmso solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/001158
Other languages
English (en)
Other versions
WO2009053549A1 (fr
Inventor
Gerard Coquerel
Baptiste Fours
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of WO2009053549A1 publication Critical patent/WO2009053549A1/fr
Publication of WO2009053549A8 publication Critical patent/WO2009053549A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le solvate de DMSO de rimonabant, son procédé de préparation et ses utilisations thérapeutiques.
PCT/FR2008/001158 2007-08-06 2008-08-04 Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant Ceased WO2009053549A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0756960 2007-08-06
FR0756960A FR2919865A1 (fr) 2007-08-06 2007-08-06 Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (2)

Publication Number Publication Date
WO2009053549A1 WO2009053549A1 (fr) 2009-04-30
WO2009053549A8 true WO2009053549A8 (fr) 2009-07-23

Family

ID=39144334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001158 Ceased WO2009053549A1 (fr) 2007-08-06 2008-08-04 Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Country Status (2)

Country Link
FR (1) FR2919865A1 (fr)
WO (1) WO2009053549A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
FR2919865A1 (fr) 2009-02-13
WO2009053549A1 (fr) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2008051942A3 (fr) Agonistes du récepteur farnésoïde x
HK1259250A1 (zh) 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂
HUE072202T2 (hu) Eltrombopag-olamint tartalmazó tabletták
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
IL206394A (en) Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
AP2010005343A0 (en) New dihydroindolone compounds, a process for theirpreparation and pharmaceutical compositions conta ining them.
EP2201011A4 (fr) Nouveaux composés présentant des squelettes d'indazole, méthodes de préparation de ceux-ci et composition pharmaceutique les contenant
WO2009055289A3 (fr) Lactames substitués à usage thérapeutique
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
IL186062A (en) Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham
IL186862A0 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
WO2009026257A8 (fr) Procédés et compositions pour contrôler la biodisponibilité de médicaments faiblement solubles
WO2006081515A3 (fr) Polymorphes d'hydrochlorure de duloxetine
WO2011014003A3 (fr) Dérivés de (+)-3-(+)-3-hydroxymorphinan utilisés comme neuroprotecteurs
IL192963A0 (en) Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same
WO2009053549A8 (fr) Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2009124734A3 (fr) Dérivés de sulfonamide substitués
PL1999112T3 (pl) Podstawione 2-amino-4-fenylo-dihydrochinoliny, sposób ich wytwarzania, ich zastosowanie jako leku i lek je zawierający
AP2012006352A0 (en) AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same.
WO2007139984A3 (fr) Polymorphes de chlorhydrate de duloxétine
EP1994003A4 (fr) Dérivés de pipéridine, leur procédé de synthèse, leur emploi en tant qu'agents thérapeutiques et les compositions pharmaceutiques les incluant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842355

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08842355

Country of ref document: EP

Kind code of ref document: A1